Resources
- FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) - First CD19-targeted ADC
- ADC Drugs: Some Challenges To Be Solved
- Trophoblast Glycoprotein (TPGB/5T4): A New Target For ADC Drugs
- Emerging drugs for the treatment of PNH
- Peptide PROTAC in Drug Development
- FGF21 agonist for MASH: Current Status
- In Vivo CAR-T Delivery: mRNA-LNP System
- Next-Generation mRNA-LNPs: Strategies to Reduce Anti-PEG Antibody Responses
- CD388, a Novel Drug Fc-Conjugate (DFC) to Prevent Influenza Infection
- PEG Lipids: Definition, Structure & Key Applications
